	Area of Research	Phase I	Phase II	Phase III	Regulatory Filing & Approval[a]	Post-Approval Research[b]
Multiple Myeloma (MM)						
REVLIMID® (lenalidomide)	Relapsed/refractory					
	Newly diagnosed					
	Maintenance					
POMALYST®/IMNOVID® (US/EU) (pomalidomide)	Relapsed/refractory[c]					
THALOMID®/Thalidomide Celgene® (US/EU) (thalidomide)	Newly diagnosed					
Myelodysplastic Syndromes (MDS)						
VIDAZA® (azacitidine for injection)						
REVLIMID® (lenalidomide)	Deletion 5q					
	Non-deletion 5q					
CC-486	Lower-risk					
Acute Myeloid Leukemia (AML)						
VIDAZA® (azacitidine for injection)	AML (20%-30% blasts) (EU)					
	AML (>30% blasts) (EU)					
REVLIMID® (lenalidomide) & VIDAZA® (azacitidine for injection)						
CC-486	Post-induction AML maintenance					
DOT 1L Inhibitor: EPZ-5676[d]						

[a]For information on approved uses, please refer to approved product labeling. [b]Includes Celgene-sponsored and Celgene-supported studies. [c]In the US, regulatory approval is based on pivotal phase II data; phase III program ongoing. [d]In collaboration with Epizyme. Inc. Epizyme

REVLIMID®, POMALYST®, IMNOVID®, THALOMID®, Thalidomide Celgene®, VIDAZA® are registered trademarks of Celgene Corporation.



[a]For information on approved uses, please refer to approved product labeling. [b]Includes Celgene-sponsored and Celgene-supported studies. [c]Filing for regulatory approval based on pivotal phase II data.

[d]In collaboration with Acceleron Pharma. ACCELERON PHARMA

ISTODAX® and REVLIMID® are registered trademarks of Celgene Corporation.

	Area of Research	Phase I	Phase II	Phase III	Regulatory Filing & Approval[a]	Post-Approval Research[b]
Solid Tumors						
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (US)/(paclitaxel formulated as albumin-bound nanoparticles) (EU)	Breast: Metastatic					
	Breast: Metastatic (first-line, triple negative)					
	Non-small cell lung: Advanced (first-line) (US, Japan)					
	Melanoma: Metastatic (first-line)					
	Pancreatic: Advanced (first-line)					
	Pancreatic: Adjuvant					
	Gastric: Metastatic (Japan)[c]					
Dual TORK Inhibitor: CC-223						
Dual TORK/DNA PK Inhibitor: CC-115						
Pleiotropic Pathway Modulator: CC-122						
CC-486						
Anti-Inflammatory						
OTEZLA® (apremilast)	Psoriatic arthritis					
	Psoriasis					
	Ankylosing spondylitis					
	Behçet's disease					
	Rheumatoid arthritis					
	Atopic dermatitis					
	Crohn's disease					
	Ulcerative colitis					
pomalidomide CC-220	Systemic sclerosis					
	Sarcoidosis					
	Systemic sclerosis					
	Cutaneous/Systemic lupus erythematosus					
Cellular Therapies						
BIOVANCE® [d,e] (decellularized, dehydrated human amniotic membrane)	Wound management					
Extracellular Matrix[f]	Wound management					
PDA-001	Crohn's disease					
PDA-002	Peripheral artery disease/Diabetic foot ulcers					

[a]For information on approved uses, please refer to approved product labeling. [b]Includes Celgene-sponsored and Celgene-supported studies. [c]Trial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd. ABRAXANE® and BIOVANCE® are registered trademarks of Celgene Corporation. [d]Regulated under Section 361 of the Public Health Service Act [e]Processed for Alliqua Biomedical by Celgene Cellular Therapeutics [f]510(k) device manufactured for Alliqua Biomedical by Celgene Cellular Therapeutics

©2014 Celgene Corporation 03/14